Risk of nonpulmonary infections requiring hospitalization in spondyloarthritis

Ho Yin Chung MD1,2 | Shirley Chiu Wai Chan FHKCP1 | Frances Sze Kei Sun MBBS1

1Division of Rheumatology and Clinical Immunology, The University of Hong Kong, Hong Kong
2Chiron Medical, Hong Kong

Correspondence
Ho Yin Chung, MD, Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, 102 Pokfulam Rd, Hong Kong. Email: jameschunghoyin@gmail.com

Abstract
Objectives: To compare the risk of five nonpulmonary infections leading to hospitalization between spondyloarthritis (SpA) and nonspecific back pain (NSBP), and to identify the risk factors.

Methods: A total of 3018 patients with SpA and 2527 patients with NSBP were identified. Data from December 1995 to June 2019 was retrieved from a centralized electronic medical record system. The date of onset of five types of nonpulmonary infections including: urinary tract infection (UTI), skin infection, gastroenteritis (GE), septic arthritis, and pancreato-hepatobiliary tract infection were identified. Demographic data, comorbidities, and medications used were also retrieved. Comparative risk of each type of infection between SpA and NSBP was determined using propensity score adjustment method. Cox regression model was used to identify risk factors.

Results: Patients with SpA were younger in age, predominantly male, with fewer comorbid diabetes mellitus (DM), renal impairment, and depression. Compared with NSBP, patients with SpA had higher risk of UTI (hazard ratio [HR] 1.91; \( p < .001 \)), skin infection (HR 1.79; \( p < .001 \)), and septic arthritis (HR 4.57; \( p = .04 \)). Risk of GE (HR 1.42; \( p = 1.00 \)), and pancreato-hepatobiliary tract infection (HR 1.67; \( p = .06 \)) were not increased. Infliximab was an independent risk factor for UTI (HR 2.21; \( p = .04 \)). Duration of steroid therapy >6 months (HR 2.22; \( p < .001 \)), smoker (HR 1.81; \( p < .001 \)), and psoriasis (HR 2.47; \( p < .001 \)) were risk factors for skin infection.

Conclusion: SpA was associated with increased risk of UTI, skin infection, and septic arthritis. Infliximab, prolonged steroid therapy, smoking, and psoriasis were associated risk factors.

Keywords
infections, infliximab, psoriasis, spondyloarthritis, steroids, urinary tract infection

Ho Yin Chung and Shirley Chiu Wai Chan contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Spondyloarthritis (SpA) is a spectrum of rheumatic diseases characterized by inflammation of the spine and sacroiliac (SI) joints, peripheral arthritis, and enthesitis. The prevalence of SpA varies across the world, ranging from 0.2% in southeast Asia to 1.6% in the Northern Arctic region. Ankylosing spondylitis (AS) is the prototypic disease, which predominantly affects young men. In contrast, there is no gender disparity in the prevalence of nonradiographic axial SpA. The treatment of SpA often includes the use of nonsteroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying antirheumatic drugs, and biologics (such as antitumor necrosis factor [anti-TNF] and anti-interleukin-17 [anti-IL17]).

SpA is associated with increased risk of comorbidities including cardiovascular events, metabolic syndrome, malignancies, and infections, all of which contribute to excess morbidity and mortality. Acquired immunodeficiency secondary to pharmacologic therapy may further increase the risk. Compared with data in rheumatoid arthritis (RA), this association is less well established in SpA. A meta-analysis of randomized controlled trials (RCT) found no increased risk of infection in patients with ankylosing spondylitis (AS) on anti-TNF therapy. However, generalizability was limited by the inclusion of relatively few studies in highly selective populations with short study durations. On the other hand, a series of recent observational studies found that disease-modifying antirheumatic drugs (DMARDs) and prolonged use of steroids were associated with herpes zoster and tuberculosis infection. A recent multicenter cohort demonstrated an increased risk of community-acquired pneumonia in SpA compared with nonspecific back pain (NSBP). Further investigation using real-life data to delineate the risk of other nonpulmonary infections is therefore important for the prevention of infection and guiding public policy.

We performed a retrospective study using a territory-wide electronic healthcare database to identify the risk of the five most prevalent nonpulmonary infections requiring hospitalization in our cohort. The incidence of infections was compared between SpA and NSBP. Associated risk factors were identified using regression analysis.

2 | METHODS

Data from December 1995 to June 2019 were retrieved from the Hospital Authority Clinical Management System (CMS), a centralized database established in 1995 of electronic medical records from all public hospitals in Hong Kong. Patients with an expert diagnosis of SpA, AS, SpA with psoriasis (PsO), inflammatory bowel disease (IBD) associated SpA, reactive arthritis (ReA), undifferentiated SpA (uSpA), and human leukocyte antigen (HLA) associated uveitis from 11 rheumatology centers (Queen Mary Hospital, Grantham Hospital, Tung Wah Hospital, Caritas Medical Center, Pamela Youde Nethersole Hospital, Tseung Kwan O Hospital, Queen Elizabeth Hospital, Kwong Wah Hospital, Alice Ho Miu Ling Nethersole Hospital, Pok Oi Hospital, and Prince of Wales Hospital) were included. All patients with NSBP from an orthopedic unit (Queen Mary Hospital) were also included as controls. NSBP was defined as back pain without a specific and identified pathology such as trauma, infection, tumor, deformity, or nerve compression. Patients with coexisting rheumatologic disease in the control group were excluded from analyses. Data were manually retrieved by the author (HYC) and randomly rechecked by another author (SCWC).

The five most prevalent nonpulmonary infections in this cohort were urinary tract infection (UTI), skin infection, gastroenteritis (GE), septic arthritis, and pancreato-hepatobiliary tract infection. Urinary tract infections included both pyelonephritis and lower urinary tract infection. Skin infection encompassed cellulitis and skin abscess. Pancreato-hepatobiliary tract infection included liver abscesses, pancreatitis, cholangitis, and cholecystitis. Diagnosis was made clinically by the managing physician, with or without confirmatory microbiology results. Date of infection and cultured micro-organisms were recorded. Mortalities as a result of the mentioned infections were also recorded.

Demographic data included age, sex, ethnicity, and smoking and drinking status. Medications used within one month of first onset of infection were recorded. These include nonsteroidal anti-inflammatory drug (NSAID), sulfasalazine, methotrexate (MTX), leflunomide, etanercept, infliximab, adalimumab, golimumab, certolizumab, secukinumab, and steroids for greater than 6 months. Comorbidities include history of PsO, IBD, diabetes mellitus (DM), renal impairment, depression, organ transplant, cerebrovascular accident (CVA), human immunodeficiency virus (HIV) infection, intravenous drug use (IVDU), and cirrhosis. Renal impairment was defined as chronic kidney disease Stage 3 or above, according to the Kidney Disease Improving Global Outcomes (KDIGO) 2012 clinical practice guidelines. CVA included both ischemic and hemorrhagic stroke and excluded transient ischaemic attack (TIA). Antero-posterior radiographs of the lumbosacral spine were read by one author (SCWC), and sacroilitis was scored.
according to the modified New York (mNY) criteria. Bilateral Grade 2 or unilateral Grade 3 or above was defined as radiographic AS.

The clinical outcomes assessed were the first onset of the five types of nonpulmonary infections. Duration of follow-up was defined as the time between the initial assessment at the rheumatology or orthopedic clinic and one of the following end-points: end of the study, day of discharge from the clinic, hospitalization due to infection, and death.

### 2.1 Statistical analyses

Independent t test and \( \chi^2 \) test were used to compare the continuous and categorical variables respectively between patients with SpA and NSBP. Normality test was done using histograms. Crude incidence rates were reported as the number of the first episode of the respective non-pulmonary infection per 1000 patient-years.

Propensity score adjustment method was used to compare the risk of the five types of nonpulmonary infection between patients with SpA and NSBP. Demographic variables, known or potential risk factors for infection were included in the logistic regression to calculate the propensity score. Factors included in the propensity score calculation were age, ethnicity, sex, smoker, drinker, NSAID, steroid for more than 6 months, DM, renal impairment, malignancy, depression, history of organ transplant, CVA, HIV infection, IVDA, and cirrhosis. Cox regression model was used to determine the risk of individual non-pulmonary infections in SpA leading to hospitalization after propensity score adjustment.

The mentioned confounding factors, medications, and radiographic AS were also used for screening of potential risk factors of each nonpulmonary infection associated with SpA. This was done by the univariate Cox Regression model. Significant factors with a \( p \) value of <.1 in the univariate analyses were included in multivariate Cox Regression model using “enter” mode. Apart from NSAID and steroid for more than 6 months, medications included in the univariate Cox regression models were sulfasalazine, methotrexate (MTX), leflunomide, etanercept, infliximab, adalimumab, golimumab, certolizumab, and secukinumab. Results were reported as hazard ratio (HR) with 95% confidence interval (CI). All statistics were performed using the International Business Machines Corporation Statistical Package for the Social Sciences (IBM SPSS) package 25.0. Unless specified, a \( p \) value of less than .05 was defined as statistically significant. Listwise deletion was performed for missing data.

### 2.2 Ethics approval

The study was approved by the ethics committee of the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (reference number UW 18-263). The Institutional Review Board waived the need for informed consent since personal information had been deidentified in our study. The study was conducted in accordance with the Declaration of Helsinki and the guidance of Good Clinical Practice, November 30, 2006.

### 3 RESULTS

Baseline characteristics of 3018 patients with SpA and 2527 patients with NSBP are shown in Table 1. The SpA group was characterized by younger age, male predominance, history of smoking and drinking, more NSAIDs and steroid use, less comorbidities including DM, renal impairment, and depression, and greater prevalence of skin infection and septic arthritis. The NSBP group had a longer duration of follow-up. Within the SpA group, most met the criteria for radiographic AS, while IBD-related SpA was rare. The most common conventional (c) and biologic (b) DMARDs used were sulfasalazine and etanercept respectively.

#### 3.1 Crude incidence rates and risk of nonpulmonary infections

Crude incidence rates of each of the hospitalized nonpulmonary infections presented in Table 2 show that skin infection (5.3 per 1000 patient-years) and septic arthritis (0.4 per 1000 patient-years) were the highest and lowest respectively.

Propensity score adjusted risks of hospitalized nonpulmonary infections in SpA with reference to NSBP were: UTI (HR 1.91, 95% CI 1.37–2.65, \( p < .001 \)), skin infection (HR 1.79, 95% CI 1.31–2.43, \( p < .001 \)), GE (HR 1.42, 95% CI 0.94–2.16, \( p = 1.00 \)), pancreato-hepatobiliary infection (HR 1.67, 95% CI 0.98–2.83, \( p = .06 \)), and septic arthritis (HR 4.57, 95% CI 1.10–18.98, \( p = .04 \)).

The only nonpulmonary infection related death occurred in the SpA group due to pancreato-hepatobiliary tract infection. No deaths occurred in the NSBP group.
|                        | Patients with SpA \( (n = 3018) \) | Patients with NSBP \( (n = 2527) \) | \( p \) Value |
|------------------------|------------------------------------|------------------------------------|--------------|
| **Demographics**       |                                    |                                    |              |
| Age (years) (mean ± SD)| 49.6 ± 14.5                        | 62.1 ± 15.0                        | <.001        |
| Chinese ethnicity      | 2985/3018 (98.9%)                  | 2487/2527 (98.4%)                 | .11         |
| Male sex               | 2058/3018 (68.2%)                  | 914/2527 (36.2%)                  | <.001        |
| Smoker                 | 886/2975 (29.8%)                   | 455/2422 (18.8%)                  | <.001        |
| Drinker                | 245/2975 (8.2%)                    | 155/2422 (6.4%)                   | .01         |
| Follow-up duration (years) | 9.5 ± 6.0                         | 13.9 ± 5.8                        | <.001        |
| **Medications**        |                                    |                                    |              |
| On NSAID               | 2863/3018 (94.9%)                  | 2120/2527 (83.9%)                 | <.001        |
| On cDMARDs             | 1645/3018 (54.5%)                  | 0/2527 (0.0%)                     |              |
| On SASP                | 1293/3018 (42.8%)                  | 0/2527 (0.0%)                     |              |
| On MTX                 | 790/3018 (26.2%)                   | 0/2527 (0.0%)                     |              |
| On leflunomide         | 164/3018 (5.4%)                    | 0/2527 (0.0%)                     |              |
| On bDMARDs             | 734/3018 (24.3%)                   | 0/2526 (0.0%)                     |              |
| On etanercept          | 280/3018 (9.3%)                    | 0/2527 (0.0%)                     |              |
| On infliximab          | 107/3018 (3.5%)                    | 0/2527 (0.0%)                     |              |
| On adalimumab          | 243/3018 (8.1%)                    | 0/2527 (0.0%)                     |              |
| On golimumab           | 201/3018 (6.7%)                    | 0/2527 (0.0%)                     |              |
| On certolizumab        | 43/3018 (1.4%)                     | 0/2527 (0.0%)                     |              |
| On secukinumab         | 75/3018 (2.5%)                     | 0/2527 (0.0%)                     |              |
| On steroid >1/2 year   | 164/3018 (5.4%)                    | 13/2527 (0.5%)                    | <.001        |
| **Comorbidities**      |                                    |                                    |              |
| History of psoriasis   | 655/3018 (21.7%)                   | 0/2527 (0.0%)                     | <.001        |
| Inflammatory bowel disease | 47/3018 (1.6%)                    | 0/2527 (0.0%)                     | <.001        |
| Radiological AS        | 1971/2917 (67.6%)                  | 0/2527 (0.0%)                     | <.001        |
| DM                     | 273/3018 (9.0%)                    | 394/2527 (15.6%)                  | <.001        |
| Renal impairment (stage 3 or above chronic kidney disease) | 187/3018 (6.2%) | 329/2527 (13.0%) | <.001 |
| Depression             | 138/3018 (4.6%)                    | 257/2527 (10.2%)                  | <.001        |
| History of organ transplant | 2/3018 (0.1%)                  | 7/2527 (0.3%)                     | .052         |
| History of cerebrovascular accident | 103/3018 (3.4%)                    | 89/2527 (3.5%)                     | .83          |
| HIV infection          | 2/3018 (0.1%)                     | 1/2527 (0.0%)                     | .67          |
| IV drug addict         | 1/3018 (0.0%)                     | 4/2527 (0.2%)                     | .12          |
| Cirrhosis              | 9/3018 (0.3%)                     | 12/2527 (0.5%)                    | .29          |
| **Infections**         |                                    |                                    |              |
| Urinary tract infection | 96/3018 (3.2%)                   | 101/2527 (4.0%)                   | .10          |
| Skin infection         | 147/3018 (4.9%)                    | 91/2527 (3.6%)                    | .02          |
| Gastroenteritis        | 76/3018 (2.5%)                     | 50/2527 (2.0%)                    | .18          |
3.2 | Risk factors for nonpulmonary infections requiring hospitalization

Cox regression models were built for UTI, skin infection, and septic arthritis—the non-pulmonary infections found to be more susceptible in patients with SpA. Univariate Cox regression models with UTI as the dependent variable found statistically significant ($p < .1$) associations with age, Chinese ethnicity, male sex, PsO, radiographic AS, infliximab, steroid therapy greater than 6 months, chronic renal impairment, malignancy, and CVA. Multivariate Cox regression analysis found Chinese ethnicity, male sex, infliximab, chronic renal impairment, and CVA were independent risk factors (Table 3).

In the univariate Cox regression models using skin infection as dependent variables, smoker, history of PsO, sulfasalazine, methotrexate, leflunomide, adalimumab, steroid for more than 6 months, DM, chronic renal impairment, history of organ transplant, and CVA had significant associations ($p < .1$). Multiple Cox regression analysis showed smoking, history of PsO, steroids for more than 6 months, and chronic renal impairment were independent risk factors for skin infection leading to hospitalization in SpA (Table 4).

In the univariate Cox regression models using septic arthritis as dependent variables, sulfasalazine, adalimumab, and malignancy had significant associations ($p < .1$). Multivariate Cox regression analysis showed only malignancy was the independent risk factor for septic arthritis leading to hospitalization in SpA (Table 5).

### 3.3 Microorganisms identified

The three most prevalent microorganisms found in each type of infection were similar in both groups, except for pancreato-hepatobiliary tract infection in which *Escherichia coli* was more prevalent in NSBP (Table 6).

### 3.4 Missing values

Missing values constituted less than 5% of the study population, and hence inconsequential. Out of a total of 5545 patients, radiographs of the lumbosacral spine were missing in 102 (1.8%), and smoking and drinking status were missing in 148 (2.7%).

---

**Table 1** (Continued)

| Patients with SpA ($n = 3018$) | Patients with NSBP ($n = 2527$) | $p$ Value |
|-------------------------------|-------------------------------|------------|
| Pancreato-hepatobiliary tract infection | 35/2018 (1.2%) | 41/2527 (1.6%) | .14 |
| Septic arthritis | 12/3018 (0.4%) | 3/2527 (0.1%) | .05 |

Abbreviations: AS, ankylosing spondylitis; bDMARDs, biological disease-modifying antirheumatic drugs; cDMARDs, conventional disease-modifying antirheumatic drugs; DM, diabetes mellitus; HIV, human immunodeficiency virus; IV, intravenous; MTX, methotrexate; NSAID, nonsteroidal anti-inflammatory drug; NSBP, nonspecific back pain; SASP, sulfasalazine; SD, standard deviation; SpA, spondyloarthritis.

**Table 2** Crude incidence rates of the hospitalized nonpulmonary infections

| Patients with SpA | Patients with NSBP |
|-------------------|-------------------|
| Number of UTI | 96 | 101 |
| Patient-years | 28,311.2 | 34,474.6 |
| Incidence per 1000 patient-years | 3.4 | 2.9 |
| Number of skin infection | 147 | 91 |
| Patient-years | 27,871.7 | 34,499.3 |
| Incidence per 1000 patient-years | 5.3 | 2.6 |
| Number of GE | 76 | 50 |
| Patient-years | 28,296.0 | 34,746.4 |
| Incidence per 1000 patient-years | 2.7 | 1.4 |
| Number of pancreato-hepatobiliary infection | 35 | 41 |
| Patient-years | 28,647.1 | 34,739.1 |
| Incidence per 1000 patient-years | 1.2 | 1.2 |
| Number of septic arthritis | 12 | 3 |
| Patient-years | 28,738.9 | 35,019.0 |
| Incidence per 1000 patient-years | 0.4 | 0.1 |

Abbreviations: GE, gastroenteritis; NSBP, nonspecific back pain; SpA, spondyloarthritis; UTI, urinary tract infection.
4 | DISCUSSION

This study of real-world data in SpA showed increased risk of hospitalized non-pulmonary infections including UTI, skin infection, and septic arthritis. Rheumatic disease and treatment-specific independent risk factors for skin infection were PsO and steroids, and infliximab for UTI.

In general, rheumatic disease predisposes one to a higher risk of infection. A population-based study showed that the incidence of hospitalized infection in patients with rheumatoid arthritis (RA) was 9/100 person-years, compared to 5/100 in those without RA. Similarly, the overall risk of infection was also increased in systemic lupus erythematosus. Without exception, this study in SpA has also found an
increased adjusted risk of UTI, skin infection, and septic arthritis.

The pathogenesis of infection in SpA includes immunologic and physical factors. T helper (Th)−17 dysregulation, thought to be the central role in the pathogenesis of SpA, results in decreased production and recruitment of neutrophils, predisposing individuals to extracellular bacterial infection. Regulatory T cells (Tregs) and CD8-memory cells are also dysregulated. In patients with AS, Tregs were found to be significantly higher in synovial fluid than in peripheral blood, attenuating the proliferation of effector T

### TABLE 4 Cox regression analyses using skin infection as a dependent variable

| Characteristics                              | Univariate Cox regression models | Multivariate Cox regression | p Value | p Value |
|----------------------------------------------|---------------------------------|----------------------------|---------|---------|
| Age                                          | 1.00 (0.99–1.01)                | 1.00 (0.99–1.01)           | .81     | .81     |
| Chinese ethnicity                            | 1.12 (0.16–8.03)                | 1.12 (0.16–8.03)           | .91     | .91     |
| Male sex                                     | 1.22 (0.85–1.75)                | 1.22 (0.85–1.75)           | .28     | .28     |
| Smoker                                       | 1.66 (1.19–2.31)                | 1.66 (1.19–2.31)           | <.01    | <.01    |
| Drinker                                      | 1.28 (0.75–2.18)                | 1.28 (0.75–2.18)           | .37     | .37     |
| History of psoriasis                         | 2.87 (2.07–3.97)                | 2.87 (2.07–3.97)           | <.001   | <.001   |
| History of inflammatory bowel disease        | 0.44 (0.06–3.13)                | 0.44 (0.06–3.13)           | .41     | .41     |
| Radiographic axial SpA                       | 1.14 (0.78–1.66)                | 1.14 (0.78–1.66)           | .49     | .49     |
| NSAID                                        | 0.75 (0.37–1.53)                | 0.75 (0.37–1.53)           | .43     | .43     |
| Sulfasalazine                                | 0.75 (0.54–1.04)                | 0.75 (0.54–1.04)           | .08     | .08     |
| Methotrexate                                 | 1.62 (1.17–2.26)                | 1.62 (1.17–2.26)           | <.01    | <.01    |
| Leflunomide                                  | 2.05 (1.23–3.39)                | 2.05 (1.23–3.39)           | .01     | .01     |
| Etanercept                                   | 1.36 (0.83–2.23)                | 1.36 (0.83–2.23)           | .22     | .22     |
| Infliximab                                   | 1.58 (0.78–3.20)                | 1.58 (0.78–3.20)           | .20     | .20     |
| Adalimumab                                   | 2.34 (1.45–3.79)                | 2.34 (1.45–3.79)           | .001    | .001    |
| Golimumab                                    | 0.92 (0.47–1.81)                | 0.92 (0.47–1.81)           | .81     | .81     |
| Certolizumab                                 | 0.98 (0.24–3.95)                | 0.98 (0.24–3.95)           | .98     | .98     |
| Secukinumab                                  | 1.39 (0.57–3.39)                | 1.39 (0.57–3.39)           | .47     | .47     |
| Steroid for > ½ year                          | 2.58 (1.63–4.11)                | 2.58 (1.63–4.11)           | <.001   | <.001   |
| Diabetes mellitus                            | 1.72 (1.11–2.66)                | 1.72 (1.11–2.66)           | .02     | .02     |
| Chronic renal impairment                     | 2.52 (1.63–3.87)                | 2.52 (1.63–3.87)           | <.001   | <.001   |
| Malignancy                                   | 1.27 (0.65–2.49)                | 1.27 (0.65–2.49)           | .49     | .49     |
| Depression                                   | 1.13 (0.55–2.30)                | 1.13 (0.55–2.30)           | .75     | .75     |
| History of organ transplant                  | 9.04 (1.26–64.76)               | 9.04 (1.26–64.76)          | .03     | .03     |
| Cerebrovascular accident                     | 1.79 (0.96–3.31)                | 1.79 (0.96–3.31)           | .07     | .07     |
| HIV infection                                | 0.50 (0.00 to >999)             | 0.50 (0.00 to >999)        | .87     | .87     |
| IV drug addict                               | 0.50 (0.00 to >999)             | 0.50 (0.00 to >999)        | .87     | .87     |
| Cirrhosis                                    | 1.91 (0.27–13.65)               | 1.91 (0.27–13.65)          | .52     | .52     |

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IV, intravenous; NSAID, nonsteroidal anti-inflammatory drug; SpA, spondyloarthritis.
Little is known regarding the effects of such alteration in T cell compositions. It is possible that the attenuated effector T cells response may result in impaired host defense against infections. Urinary stasis as a result of immobility was shown to increase the risk of UTI while joint pathology is associated with septic arthritis. The microorganisms identified were common causes of infections in their respective sites. There were no significant differences in the pathogens between SpA and NSBP, except in hepatobiliary infections. *E. coli* and *Klebsiella pneumoniae* are both common causes of hepatobiliary infections. HLA-B27 has been linked to the perpetuation of *Klebsiella* infection and the pathogenesis of ankylosing spondylitis. This might explain the observation of a higher frequency of *E. coli* in causing hepatobiliary infection among patients with NSBP compared with SpA.

### Table 5: Cox regression analyses using septic arthritis as a dependent variable

| Characteristics                        | Univariate Cox regression models | Multivariate Cox regression models |
|----------------------------------------|----------------------------------|-----------------------------------|
|                                        | Hazard ratio (95% CI) | p Value | Hazard ratio (95% CI) | p Value |
| Age                                    | 1.01 (0.96–1.05) | .81    |                     |         |
| Chinese ethnicity                      | 20.32 (0.00 to >999) | .85    |                     |         |
| Male sex                               | 2.35 (0.52–10.73) | .27    |                     |         |
| Smoker                                 | 1.15 (0.35–3.82) | .82    |                     |         |
| Drinker                                | 1.02 (0.13–7.88) | .99    |                     |         |
| History of psoriasis                   | 0.30 (0.04–2.34) | .25    |                     |         |
| History of inflammatory bowel disease  | 0.05 (0.00 to >999) | .77    |                     |         |
| Radiographic axial SpA                 | 1.96 (0.43–8.98) | .38    |                     |         |
| NSAID                                  | 21.44 (0.00 to >999) | .64    |                     |         |
| Sulfasalazine                          | 3.16 (0.85–11.70) | .09    | 2.91 (0.77–10.96) | .11    |
| Methotrexate                           | 1.16 (0.35–3.87) | .81    |                     |         |
| Leflunomide                            | 1.37 (0.18–10.58) | .77    |                     |         |
| Etanercept                             | 0.04 (0.00–216.35) | .47   |                     |         |
| Infliximab                             | 1.68 (0.22–13.05) | .62    |                     |         |
| Adalimumab                             | 3.89 (1.05–14.38) | .04    | 3.61 (0.95–13.71) | .06   |
| Golimumab                              | 1.35 (0.17–10.46) | .77    |                     |         |
| Certolizumab                           | 0.05 (0.00 to >999) | .79    |                     |         |
| Secukinumab                            | 3.35 (0.43–26.04) | .25    |                     |         |
| Steroid for > ½ year                   | 1.29 (0.17–9.98) | .81    |                     |         |
| Diabetes mellitus                      | 1.70 (0.37–7.75) | .50    |                     |         |
| Chronic renal impairment               | 0.04 (0.00–459.19) | .51    |                     |         |
| Malignancy                             | 3.75 (0.82–17.16) | .09    | 4.74 (1.02–22.08) | .05   |
| Depression                             | 1.74 (0.22–13.47) | .60    |                     |         |
| History of organ transplant            | 0.50 (0.00 to >999) | .95    |                     |         |
| Cerebrovascular accident               | 0.05 (0.00 to >999) | .62    |                     |         |
| HIV infection                          | 0.05 (0.00 to >999) | .96    |                     |         |
| IV drug addict                         | 0.05 (0.00 to >999) | .97    |                     |         |
| Cirrhosis                              | 0.50 (0.00 to >999) | .89    |                     |         |

**Abbreviations:** CI, confidence interval; HIV, human immunodeficiency virus; IV, intravenous; NSAID, nonsteroidal anti-inflammatory drug; SpA, spondyloarthritis.
From this data, one fatality from infection occurred in the SpA group, despite a significant proportion on immunosuppressant therapy (54.5% on cDMARDs and 24.3% on bDMARDs). A meta-analysis of RCTs in AS found low risk of serious infection (4 per 1000 patient-years) on anti-TNF drugs compared with placebo.36 Real-life data from a Canadian longitudinal observational cohort of 440 patients with SpA also showed a slight risk of serious infection.37 This study had similar findings.

Infliximab was the only DMARD found to be associated with increased risk (2.2 times compared with control) of hospitalized UTI, among other potential variables analyzed including steroids and SpA subtypes. Previous research has also consistently found that among immunosuppressants, the greatest risk of infection occurred with infliximab.36,39 Pharmacodynamic properties unique to infliximab40 that results in downregulation of interferon (IFN)-γ was not observed with etanercept.40 IFN-γ has an important role in both innate and adaptive immunity by enhancing natural killer cells, activating macrophages, and inducing expression of major histocompatibility complex (MHC) Class II molecules. Pharmacokinetically, high peak serum concentrations of infliximab up to 50 times the median trough level41 also predisposes to infection.42 Pneumonia,10 tuberculosis,10 and cutaneous herpes zoster9 were also increased with infliximab therapy. Infliximab may have distinct immunosuppressive effects that increase infection risk.

Steroid therapy for more than six months was associated with an increased risk (2.2 times compared with control) of skin infection. The immunosuppressive properties of steroids involve multiple pathways. Suppression of activation and differentiation of macrophages decreases downstream production of IL-1, IL-6, TNF, prostaglandins, and leukotrienes.43 Steroid-induced lymphopenia occurs via inhibition of T-cell activation by inhibition of IL-2, IL3, IL-4, and IL-6,43 and suppression of dendritic cell maturation and function.44 Long-term steroid therapy has been shown to increase the risk of community-acquired pneumonia11 and tuberculosis10 in SpA. Prolonged steroid therapy in SpA is not recommended45–47 by international consensus guidelines.

PsO was an independent risk factor for skin infection, with 2.5 times increased risk compared to control. Akin to SpA, patients with PsO are more susceptible to infection as a result of immune dysregulation and disruption of skin barrier function. A population-based study in the United States showed that PsO is associated with an increased

| Table 6 | Microorganisms identified in different types of hospitalized nonpulmonary infections |
|-----------------|-----------------|-----------------|-----------------|
| **Urinary tract infection (urine culture)** | **Patients with SpA** | **Patients with NSBP** | **p Value** |
| *Escherichia coli* | 43/96 (44.8%) | 49/101 (48.5%) | .60 |
| *Enterococcus* | 5/96 (5.2%) | 6/101 (5.9%) | .82 |
| *Proteus* | 3/96 (3.1%) | 6/101 (5.9%) | .34 |
| **Skin infection (wound swab for culture)** | **Patients with SpA** | **Patients with NSBP** | **p Value** |
| *Staphylococcus aureus* | 33/147 (22.4%) | 19/91 (20.9%) | .78 |
| *Pseudomonas aeruginosa* | 5/147 (3.4%) | 2/91 (2.2%) | .59 |
| *Streptococcus pneumoniae* | 4/147 (2.7%) | 3/91 (3.3%) | .80 |
| **Gastroenteritis (stool culture)** | **Patients with SpA** | **Patients with NSBP** | **p Value** |
| *Vibrio cholerae* | 2/76 (2.6%) | 4/50 (8.0%) | .17 |
| *Campylobacter jejuni* | 2/76 (2.6%) | 1/50 (2.0%) | .82 |
| *Norovirus* | 2/76 (2.6%) | 0/50 (0.0%) | .25 |
| **Hepatobiliary tract infection (bile culture)** | **Patients with SpA** | **Patients with NSBP** | **p Value** |
| *Klebsiella pneumoniae* | 8/35 (22.9%) | 4/41 (9.8%) | .12 |
| *Escherichia coli* | 1/35 (2.9%) | 8/41 (19.5%) | .03 |
| *Enterococcus faecalis* | 2/35 (5.7%) | 2/41 (4.9%) | .87 |
| **Septic arthritis (tissue culture)** | **Patients with SpA** | **Patients with NSBP** | **p Value** |
| *Staphylococcus aureus* | 3/12 (25.0%) | 1/3 (33.3%) | .77 |
| *Streptococcus pneumoniae* | 2/12 (16.7%) | 0/3 (0.0%) | .45 |

Abbreviations: NSBP, nonspecific back pain; SpA, spondyloarthritis.
risk of a range of infections including cellulitis, infectious arthritis, viral infection, tuberculosis, osteomyelitis, meningitis, encephalitis, septicemia, and enterocolitis. In addition, hospitalization rates in PsO were affected by socioeconomic factors, suggesting inadequate treatment could result in an increased risk of infection.

In our study, the increased risk of septic arthritis in SpA was not due to DMARD therapy. Other conditions involving the joints such as osteoarthritis (OA) and RA also had an increased risk of infectious arthritis. Although the prevalence in our cohort was lower than that of RA, septic arthritis in SpA is likely to have similar pathogenesis. The increased risk of septic arthritis with malignancies may be indirectly related to treatment such as chemotherapy and immunotherapy, which was not addressed in this study. Given the small number of cases with septic arthritis, the current study did not have adequate power to detect the effect of age, DM, and alcohol. Other potential risk factors including joint deformity, disease activity, and functional impairment were not recorded in the electronic database.

Other risk factors for non-pulmonary infections identified in the present study were consistent with previous findings. Non-Chinese ethnicity, female gender, chronic renal impairment, and CVA were risk factors for UTI; smoking, and chronic renal impairment for skin infection; and malignancy for septic arthritis. Although diagnostic inaccuracies may occur, microorganisms identified were similar in both SpA and NSBP groups. This suggests that infection in SpA likely shares similar modes of transmission as the general population.

4.1 Limitations and future perspectives

Nonspecific back pain was selected as a surrogate for the general population, which may be less than ideal. Patients with NSBP were selected for their immunocompetency, and absence of obvious additional risk factors for nonpulmonary infections, in which comprehensive medical records were available. Other limitations stem from its retrospective nature. The diagnosis of infection was based on clinical findings, with or without confirmatory microbiology tests. However, similar percentages with missing microbiological results were found in both groups, and hence similar margin of error. To minimize bias, propensity score adjustments were done to enhance validity of comparisons, however, these did not include disease activity, joint damage, functional status, and body weight. Therefore, the study could not account for all potential confounding factors, and could only provide insights into associations between conditions. Similarly, our study did not include PsO disease severity and therefore could not conclude whether adequately treated patients would be at lower risk of infections. Recurrence of infections and mortality were not included, which would otherwise provide a broader context of risk over time. As the data encompassed over 24 years, sensitivity analysis was used to adjust for temporal advances in treatment. As mentioned previously, some of the clinical outcomes (e.g., septic arthritis) were small. There were also few patients on the newer bDMARDs (e.g., secukinumab), therefore the effect of these on the risk of infections is unknown. A large prospective cohort to assess disease activity, chronicity, and functional impairment of SpA could provide answers to the unresolved questions.

5 Conclusion

SpA was associated with an increased risk of UTI, skin infection, and septic arthritis compared with NSBP. Independent risk factors include infliximab, duration of steroid therapy greater than six months, and PsO. Rheumatologists should consider aim to avoid long-term steroid to help prevent nonpulmonary infections in SpA. Further studies are needed to ascertain the relationship between disease severity and the risk of major infections. Monitoring for UTI may be appropriate with the use of infliximab.

Acknowledgement

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data are available from Dr Ho Yin Chung upon reasonable request.

ORCID

Ho Yin Chung https://orcid.org/0000-0002-0175-1346

References

1. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018;30(2):137-143.
2. Mathieu S, Soubrier M. Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis. Ann Rheum Dis. 2019;78(6):e357.
3. Giraud C, Lambert C, Dutheil F, Pereira B, Soubrier M, Tournadre A. The relationship between weight status and metabolic syndrome in patients with rheumatoid arthritis and spondyloarthritis. Joint Bone Spine. 2021;88(1):105059.
4. Chang CC, Chang CW, Nguyen PA, et al. Ankylosing spondylitis and risk of cancer. Oncol Lett. 2017;14:1315-1322.
5. Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under
6. Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(suppl):11-34.

7. Singh JA, Cameron C, Noorboloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015; 386(9990):258-265.

8. Xu Z, Xu P, Fan W, et al. Risk of infection in patients with spondylarthropathy and ankylosing spondylitis receiving anti-tumor necrosis factor therapy: a meta-analysis of randomized controlled trials. Exp Ther Med. 2017;14(4):3491-3500.

9. Wong SCT, Li IWS, Ng AHY, Lau CS, Chung HY. Risk of serious infection in patients with spondylarthropathy treated with conventional and biologic disease-modifying antirheumatic drugs. Int J Rheum Dis. 2020;23(2):189-196.

10. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Am J Kidney Dis. 2013;55(5):S1-S252.

11. Wong SCT, Li IWS, Ng AHY, Lau CS, Chung HY. Risk of serious infection in patients with spondylarthropathy treated with conventional and biologic disease-modifying antirheumatic drugs. Int J Rheum Dis. 2020;23(2):189-196.

12. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):S25-S30.

13. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.

14. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399-424.

15. Rowe TA, Mckoy JM. Sepsis in older adults. Infect Dis Clin North Am. 2017;31(4):731-742.

16. Moss M. Epidemiology of sepsis: race, sex, and chronic alcohol abuse. Clin Infect Dis. 2005;41(Suppl 7):S490-S497.

17. Huttunen R, Heikkinen T, Syrjanen J. Smoking and the outcome of infection. J Intern Med. 2011;269(3):258-269.

18. Chaudhary NS, Donnelly JP, Moore JX, Baddley JW, Safford MM, Wang HE. Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort. Crit Care. 2017;21(1):185.

19. Knapp S. Diabetes and infection: is there a link? – A mini-review. Gerontology. 2013;59(2):99-104.

20. Syed-Ahmen M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):8-15.

21. Mirouse A, Vigneron C, Llitjos JF, et al. Sepsis and cancer: an interplay of friends and foes. Am J Respir Crit Care Med. 2020;202(12):1625-1635.

22. Askim Å, Gustad LT, Paulsen J, et al. Anxiety and depression symptoms in a general population and future risk of bloodstream infection: the HUNT study. Psychosom Med. 2018;80(7):673-679.

23. Bafi AT, Tomotani DY, de Freitas FG. Sepsis in solid-organ transplant patients. Shock. 2017;47(4 Suppl 1):12-16.

24. Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010;9(1):105-118.

25. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol. 2011;6:223-248.

26. Jackson KA, Bohm MK, Brooks JT, et al. Invasive methicillin-resistant staphylococcus aureus infections among persons who inject drugs – six sites, 2005-2016. MMWR Morb Mortal Wkly Rep. 2018;67(22):625-628.

27. Ascione T, Di Flumeri G, Bocci G, De Caro F. Infections in patients affected by liver cirrhosis: an update. Infez Med. 2017; 25(2):91-97.

28. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287-2293.

29. Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. Arthritis Care Res (Hoboken). 2015;67(8):1078-1085.

30. Mauro D, Simone D, Bucci L, Ciccia F. Novel immune cell phenotypes in spondyloarthritis pathogenesis. Semin Immunopathol. 2021;43(2):265-277.

31. Appel H, Wu P, Scheer R, et al. Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. J Rheumatol. 2011;38(11):2445-2451.

32. Cao D, van Vollenhoven R, Klareskog L, Trollimo C, Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6(4):R335-R346.

33. Wiedl A, Forch S, Fenwick A, Mayr E. Incidence, risk-factors and associated mortality of complications in orthogeriatric co-managed inpatients. Geriatr Orthop Surg Rehabil. 2021;12: 1251459321998314.

34. Mathews CJ, Weston VC, Jones A, Field M, Coakley G. Bacterial septic arthritis: results from a longitudinal observational cohort. Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Arthritis Res Ther. 2015;54(1):156.

35. Rashid T, Wilson C, Ebiringer A. The link between ankylosing spondylitis, Crohn’s disease, Klebsiella, and starch consumption. Clin Dev Immunol. 2013;2013:872632.

36. Fouque-Aubert A, Jette-Paulin L, Combesure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Rheum Dis. 2016;75(9):1756-1761.

37. Wallis D, Thavaneswaran A, Haroon N, Ayeast R, Inman RD. Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Rheumatology (Oxford). 2015;54(1):152-156.

38. Mok CC, Chan KY, Lee KL, Tam LSM, Lee KW. Hong Kong Society of Rheumatology. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Int J Rheum Dis. 2014;17(Suppl 3):1-8.

39. Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28(7):846-852.
40. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leucocytes. *J Investig Dermatol Symp Proc*. 2007;12(1):9-15.

41. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2002;46(6):1451-1459.

42. Bejan-Angoulvant T, Ternant D, Daoued F, et al. Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis. *Arthritis Rheumatol*. 2017;69(1):108-113.

43. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. *Ann Intern Med*. 1993;119(12):1198-1208.

44. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. *Mol Cell Endocrinol*. 2011;335(1):2-13.

45. Tam LS, Wei JC, Aggarwal A, et al. 2018 APLAR axial spondyloarthritis treatment recommendations. *Int J Rheum Dis*. 2019;22(3):340-356.

46. Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017;76(6):978-991.

47. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2016;68(2):282-298.

48. Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. *J Am Acad Dermatol*. 2016;75(2):287-296.

49. Hsu DY, Gordon K, Silverberg JI. The inpatient burden of psoriasis in the United States. *J Am Acad Dermatol*. 2016;75(1):33-41.

50. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum*. 2002;46(9):2287-2293.

**How to cite this article:** Chung HY, Chan SCW, Sun FSK. Risk of nonpulmonary infections requiring hospitalization in spondyloarthritis. *Immun Inflamm Dis*. 2022;10:e615. doi:10.1002/iid3.615